Tonix Pharmaceuticals is enrolling participants in a Phase 3 trial for fibromyalgia, the RALLY study.
For more information, please visit www.RALLYStudy.com or www.clinicaltrials.gov (NCT04508621).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease

December 12, 2017 • 7:00 AM EST

Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor Conference

November 30, 2017 • 7:00 AM EST

Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update

November 7, 2017 • 7:00 AM EST

Tonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering Conference

November 1, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSD

October 17, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference

October 12, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Presented at the 2nd Annual Cohen Veterans Care Summit in Washington, D.C.

September 29, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

September 14, 2017 • 4:05 PM EDT

Tonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors

September 14, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

September 6, 2017 • 7:00 AM EDT

Show All

News / Press Releases : Press Releases